SGLT2 Inhibitor Use After Takotsubo Syndrome Linked to Lower Mortality

Early initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors after Takotsubo syndrome was associated with significantly lower all-cause mortality in a large real-world U.S. study, although reductions in cardiovascular complications were not observed. Using the TriNetX U.S. Collaborative Network, researchers identified adults diagnosed with Takotsubo syndrome between 2015 and 2025 and compared patients who started an SGLT2 inhibitor within 14 days with matched patients who did not. Among 1,803 matched pairs, early SGLT2 inhibitor use was associated with lower all-cause mortality (8.1% vs 13.6%; hazard ratio 0.71, p=0.001). However, no significant differences were found in heart failure hospitalization, cardiogenic shock, cardiac arrest, or major adverse cardiovascular events. The mortality benefit remained directionally consistent even after excluding patients with COVID-19 or diabetes mellitus, suggesting a potentially broader protective effect following Takotsubo syndrome. Source: https://www.ajconline.org/